A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα-positive solid tumours: Results in the endometrial cancer (EC) cohort

被引：2

作者：

Cristea, M. C. ^{[1
]}

Frankel, P. ^{[2
]}

Synold, T. ^{[3
]}

Stewart, D. B. ^{[1
]}

Wang, E. ^{[1
]}

Jung, A. ^{[4
]}

Wilczynski, S. ^{[5
]}

Tran, M. ^{[5
]}

Konecny, G. E. ^{[6
]}

Eng, M. ^{[7
]}

Kilpatrick, L. ^{[8
]}

Chen, Y-J. ^{[9
]}

Glaser, S. ^{[9
]}

Han, E. ^{[10
]}

Dellinger, T. ^{[10
]}

Hakim, A. ^{[10
]}

Lee, S. ^{[10
]}

Morgan, R. J. ^{[1
]}

Rodriguez, L. ^{[10
]}

Wakabayashi, M. ^{[10
]}

机构：

[1] City Hope Comprehens Canc Ctr, Med Oncol, Duarte, CA USA

[2] City Hope Comprehens Canc Ctr, Dept Computat & Quantitat Med, Duarte, CA USA

[3] City Hope Natl Med Ctr, Canc Biol, Duarte, CA USA

[4] City Hope Comprehens Canc Ctr, Diagnost Radiol, Duarte, CA USA

[5] City Hope Comprehens Canc Ctr, Div Program, Duarte, CA USA

[6] Univ Calif Los Angeles, Dept Med, David Geffen Sch, Los Angeles, CA 90024 USA

[7] City Hope Natl Med Ctr, Div Program, Duarte, CA USA

[8] City Hope Natl Med Ctr, Shared Rsc Clin Trial Off, Duarte, CA USA

[9] City Hope Comprehens Canc Ctr, Radiat Oncol, Duarte, CA USA

[10] City Hope Comprehens Canc Ctr, Surg, Duarte, CA USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.1002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

863P

引用

页码：S639 / S639

页数：1

共 50 条

[21] Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts.
Moore, Kathleen N.
Matulonis, Ursula A.
O'Malley, David M.
Konner, Jason A.
Martin, Lainie P.
Perez, Raymond P.
Bauer, Todd Michael
Gilbert, Lucy
Seward, Shelly Marie
Oza, Amit M.
Ruiz-Soto, Rodrigo
Birrer, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[22] TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors-Early analysis in pts with advanced/metastatic endometrial cancer (EC).
Santin, Alessandro
Corr, Bradley
Spira, Alexander I.
Willmott, Lyndsay
Butrynski, James Edward
Tse, Ka Yu
Patel, Jilpa
Mekan, Sabeen
Wu, Tia
Dumbrava, Ecaterina Elena
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[23] FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)
Moore, K.
Oza, A.
Colombo, N.
Oaknin, A.
Scambia, G.
Lorusso, D.
Farias-Eisner, R.
Banerjee, S.
Murphy, C.
Tanyi, J.
Hirte, H.
Konner, J.
Lim, P.
Hayes, M. Prasad
Monk, B.
Kim, S.
Wang, J.
Pautier, P.
Vergote, I.
Birrer, M.
ANNALS OF ONCOLOGY, 2019, 30
[24] Results of a phase I study of GS-5745 in combination with gemcitabine and nab-paclitaxel in patients (pts) with advanced pancreatic cancer.
Bendell, Johanna C.
Huang, Xi
Smith, Victoria
Maltzman, Julia D.
Starodub, Alexander
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[25] FORWARD II: A phase Ib study to evaluate the safety, tolerability and pharmacokinetics of mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin or pegylated liposomal doxorubicin in adults with folate receptor alpha (FRα)-positive advanced epithelial ovarian cancer (EOC), primary peritoneal, fallopian tube, or endometrial cancer.
O'Malley, David M.
Martin, Lainie P.
Moore, Kathleen N.
Nepert, Dale L.
Ruiz-Soto, Rodrigo
Vergote, Ignace
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[26] FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer.
Moore, Kathleen N.
Vergote, Ignace
Oaknin, Ana
Colombo, Nicoletta
Banerjee, Susana N.
Oza, Amit M.
Pautier, Patricia
Kelly, Catherine Margaret
Malek, Karim S.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[27] Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase I/II study.
Santin, Alessandro
Komiya, Takefumi
Goldenberg, David M.
Sharkey, Robert M.
Hong, Quan
Wegener, William A.
Goswami, Trishna
Bardia, Aditya
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[28] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.
O'Malley, David M.
Martin, Lainie P.
Gilbert, Lucy
Vergote, Ignace
Matulonis, Ursula A.
Birrer, Michael J.
Castro, Cesar Martin
Malek, Karim S.
Gonzalez-Martin, Antonio
Moore, Kathleen N.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[29] A phase I study of pemetrexed (P) plus gemcitabine (G) in relapsed ovarian cancer (OC): Dosing results and evidence of activity.
Hensley, M. L.
Derosa, F.
Gerst, S. R.
Sabbatini, P.
Dupont, J.
Konner, J.
Goss, T.
Orlando, M.
Wang, Y.
Aghajanian, C.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 276S - 276S
[30] Gemcitabine (G) in combination radiationtherapy (RT) in stage III-IV pancreatic cancer: First results of a current Phase I study
Maurer, U
Stegmeier, P
Bolte, R
Jungius, KP
Mueller, D
Georgi, M
EUROPEAN JOURNAL OF CANCER, 1999, 35 : S148 - S148

← 1 2 3 4 5 →